Site of Care Infusion Drugs
Blue Cross Blue Shield of Wyoming’s site of care program requires certain services that may have been received in a hospital setting to now only be authorized in the most cost-effective setting, such as an infusion center, provider’s office, or via home health including the use of subcutaneous injectables. If needed, BCBSWY will assist members with finding an appropriate site for care. All medications under this program require Prior Authorization.
If administration of the list of drugs below are not approved to be performed in an inpatient or outpatient hospital setting members can receive infusion treatments at facilities such as free-standing infusion center, doctor’s office, pharmacy, or via home health. Failure to receive the service in an approved location could result in the denial of claims. The financial responsibility of the denied amount will be the members responsibility.
Please be advised that while the medication may have been approved as medically appropriate, the member’s benefits may require this service be provided in specific locations.
If needed, our Site of Care Team can assist members with finding an appropriate site for care. Our team is available Monday-Friday, 8:00 am-5:00 pm, by calling 307-823-6095 to assist you.
Aralast
Asceniv
Bivigram
Cutaquig
Cuvitru
Flebogamma
Gamastan
Gammagard
Gammaplex
Gamunex
Hizentra
HyQvia
Octagam
Panzyga
Privigen
Vivaglobin
Xembify
Preferred Product Program
Beginning on 1/1/2026, some members may be required to receive preferred medications, including biosimilar medications for coverage. Biosimilar medications are medications that have active properties similar to the brand name medications but are typically less costly. Exceptions may apply during the prior authorization process when a contraindication is clinically documented by a health care provider.
All preferred products are listed within the medical policies posted on our public website. Below is a listing of the drug classes with preferred products.
| Drug Class | Preferred Product |
| Bevacizumab | Mvasi & Zirabev |
| Rituximab | Ruxience, Truxima, Riabni |
| Infliximab | Avsola, Inflectra |
| Viscosupplements | Durolane, Gelsyn-3, Supartz, Gel-One, Visco-3 |
| Denosumab | Jubbonti, Stobclo |
| Immune Globulins IV | Octagam, Gemmaked, Gamunix-C, Gammargard, Privigen |
| Immune Globulins SC | Hyqvia, Hizentra, Xembify, Cutaquig |
| Ustekinumab | Selarsdi, Yesintek, SteQueyma |
| Infused Iron | Feraheme, Ferrlecit, INFed, Venofer |
This program will go into effect with new prescriptions or upon authorization renewal. Typically, medical authorizations expire one year from the date of the authorization.
Questions:
Your redirection of care team is available to members and providers. If you’re currently taking one of these medications or prescribing these medications and have questions or concerns, please call 307-823-6095.